The purpose of this clinical trial is to evaluate a validated test (OncoK9) during repeated follow-up visits to demonstrate the benefit and use as a non-invasive tool in cancer detection and monitoring throughout the lifetime of a dog, to reduce cancer related morbidity and mortality.

ELIGIBILITY:

• Dogs (of any breed) over 7 years of age or
• Dogs (predisposed breed) over 4 years of age
  • Breeds highly likely to develop cancer includes: Labrador Retrievers, French bulldogs, German Shepherds, Golden Retrievers, Beagles, Rottweilers, Boxers, Siberian Husky, Bernese Mountain Dogs, Rhodesian Ridgebacks, Flat Coated Retrievers, Sottish Deerhounds, Great Danes, Irish Wolfhounds, or Mastiffs
• Willing to attend visits for blood collection, as directed (every 3-6 months), for the remainder of your dog’s life

BENEFITS:

• All study specific visits will be covered by the study
• If your dog has suspected cancer via OncoK9 test result, the study will cover some staging tests

CONTACT: If interested, please contact PennVet’s Clinical Investigations Department (VCIC) by phone: 215.573.0302 or email: vcic@vet.upenn.edu